ClinCalc Pro
Menu
3rd-generation EGFR tyrosine-kinase inhibitor

Lazertinib (Specialist drug)

Brand names: Lazcluze

Adult dose

Dose: Specialist initiation only — refer to BNF/SmPC
Route: PO
Frequency: OD

Clinical pearls

  • EGFR-mutated NSCLC (often combined with amivantamab); specialist oncology

Contraindications

  • See SmPC

Side effects

  • Rash
  • Paronychia
  • Diarrhoea
  • Hepatotoxicity
  • ILD
  • QT prolongation
  • Cardiomyopathy

Interactions

  • Strong CYP3A4 modulators
  • QT-prolonging drugs

Monitoring

  • LFTs
  • ECG
  • Echo
  • Pulmonary symptoms

Reference: BNF; SmPC; https://bnf.nice.org.uk/drugs/lazertinib-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.

Related

Curated clinical cross-links plus same-class fallbacks.